PDS Biotechnology (PDS Biotechnology) ROCE % : -82.93% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PDS Biotechnology's annualized ROCE % for the quarter that ended in Dec. 2023 was -82.93%.

PDS Biotechnology ROCE % Historical Data

The historical data trend for PDS Biotechnology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology ROCE % Chart

PDS Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-35.38

-75.80

-47.08

-62.37

-71.08

PDS Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-106.20	-52.88	-79.53	-75.31	-82.93

PDS Biotechnology ROCE % Calculation

PDS Biotechnology's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-40.142	/	( ( (77.008 - 9.821)	+	(59.39 - 13.63) )	/ 2 )
	=	-40.142	/	( (67.187	+	45.76)	/ 2 )
	=	-40.142	/	56.4735
	=	-71.08 %

PDS Biotechnology's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-38.892	/	( ( (57.188 - 9.154)	+	(59.39 - 13.63) )	/ 2 )
	=	-38.892	/	( ( 48.034	+	45.76 )	/ 2 )
	=	-38.892	/	46.897
	=	-82.93 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

PDS Biotechnology (NAS:PDSB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PDS Biotechnology ROCE % Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology (PDS Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

EU6:Germany

Address

25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Executives

Spencer D. Brown	officer: Senior VP, General Counsel	25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill	officer: Chief Financial Officer	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist	director, 10 percent owner	RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King	officer: Interim Chief Financial Office	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev	director	303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk	officer: Principal Accounting Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes	director	C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo	director, 10 percent owner, officer: President/CEO	300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood	officer: Chief Medical Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn	officer: Chief Scientific Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922